Therapeutic effect of sitagliptin combined insulin in treatment of type 2 Diabetes
10.3760/cma.j.issn.1008-1372.2014.03.018
- VernacularTitle:胰岛素联合西格列汀治疗2型糖尿病患者临床观察
- Author:
Jing WANG
;
Minxi SONG
;
Lin XU
;
Yu WANG
- Publication Type:Journal Article
- Keywords:
Insulin/therapeutic use;
Hypoglycemic agents/therapeutic use;
Diabetes mellitus,type 2/drug therapy;
Treatment outcome
- From:
Journal of Chinese Physician
2014;16(3):341-343
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect of sitagliptin combined insulin compared to those patients whose sugars were not well controlled by insulin alone.Methods The eighty type 2 Diabetes patients whose BMI≥24 kg/m2 and used insulin alone were randomly divided into sitagliptin combined insulin group (40 cases) who were given sitagliptin 100mg/d allied with insulin,an insulin group (40 cases) who were given insulin alone.After 12 weeks,the change of body mass index (BMI),fasting plasma glucose (FPG),2 h postprandial blood glucose (2 h PBG),glycosylated hemoglobin (HbA1 c),β-cell function index(HOMA-β),insulin resistance index (HOMA-IR),insulin quantities,and hypoglycemia rates were observed in two groups.Results Compared with pretherapy,the levels of FPG,2 h BG,HbAlc,HOMA-IR,and hypoglycemia rates were significantly decreased (P ＜0.05) ; BMI was increased in insulin group,while was not increased in sitagliptin combined insulin group.After the treatment,the insulin quantities were decreased in the combined group while increased in the control group (P ＜ 0.05).Conclusions Sitagliptin combined insulin can effectively control glucose levels of type 2 diabetes patients,decrease the insulin quantities and the risk of hypoglycemia,and does not increase the weight.
